ATA186692A - Pharmazeutische zusammensetzung - Google Patents

Pharmazeutische zusammensetzung

Info

Publication number
ATA186692A
ATA186692A AT0186692A AT186692A ATA186692A AT A186692 A ATA186692 A AT A186692A AT 0186692 A AT0186692 A AT 0186692A AT 186692 A AT186692 A AT 186692A AT A186692 A ATA186692 A AT A186692A
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
pharmaceutical compositions
compositions containing
treating
preparation
Prior art date
Application number
AT0186692A
Other languages
English (en)
Other versions
AT403656B (de
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ATA186692A publication Critical patent/ATA186692A/de
Application granted granted Critical
Publication of AT403656B publication Critical patent/AT403656B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0186692A 1991-09-20 1992-09-18 Pharmazeutische zusammensetzung AT403656B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919120131A GB9120131D0 (en) 1991-09-20 1991-09-20 Medicaments

Publications (2)

Publication Number Publication Date
ATA186692A true ATA186692A (de) 1997-09-15
AT403656B AT403656B (de) 1998-04-27

Family

ID=10701750

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92202832T ATE228835T1 (de) 1991-09-20 1992-09-16 Verwendung von ranitidin-wismut-zitrat in kombination mit claritromyzin oder claritromyzin und tetrazyklin zur herstellung eines arzneimittels zur behandlung gastrointestinaler beschwerden
AT0186692A AT403656B (de) 1991-09-20 1992-09-18 Pharmazeutische zusammensetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92202832T ATE228835T1 (de) 1991-09-20 1992-09-16 Verwendung von ranitidin-wismut-zitrat in kombination mit claritromyzin oder claritromyzin und tetrazyklin zur herstellung eines arzneimittels zur behandlung gastrointestinaler beschwerden

Country Status (26)

Country Link
US (3) US5674858A (de)
EP (1) EP0533281B1 (de)
JP (1) JPH0692850A (de)
KR (1) KR100257367B1 (de)
AT (2) ATE228835T1 (de)
BE (1) BE1005808A5 (de)
CA (1) CA2078579A1 (de)
CH (1) CH685372A5 (de)
CY (1) CY2012A (de)
CZ (1) CZ282840B6 (de)
DE (1) DE69232864T2 (de)
ES (1) ES2188582T3 (de)
FR (1) FR2682040B1 (de)
GB (2) GB9120131D0 (de)
HK (1) HK78197A (de)
HU (1) HU211170A9 (de)
IE (1) IE922673A1 (de)
IL (1) IL103213A (de)
IT (1) IT1262993B (de)
MX (1) MX9205313A (de)
NO (1) NO301456B1 (de)
NZ (1) NZ244390A (de)
PT (1) PT533281E (de)
RU (1) RU2116071C1 (de)
SK (1) SK280283B6 (de)
ZA (1) ZA927157B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68915272T2 (de) * 1988-10-31 1994-11-17 Sumitomo Cement Co Antireflexionsgegenstände, herstellungsverfahren und beschichtungszusammensetzungen.
CA2165344A1 (en) * 1993-06-15 1994-12-22 Peter C. Canning Immune stimulants in bacterial infections
ATE192932T1 (de) * 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
CA2189001A1 (en) * 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
EP0805815B1 (de) * 1995-01-26 2002-04-10 Nycomed Imaging A/S Verwendung von WISMUTVERBINDUNGEN zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US5900410A (en) * 1996-08-27 1999-05-04 Hartmann; John F. Monotherapy of peptic ulcers and gastritis
DE19709897A1 (de) * 1997-03-11 1998-09-17 Hoechst Ag Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
IT1296980B1 (it) * 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
AU3668000A (en) * 1999-04-29 2000-11-17 Russinsky Limited Compounds
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
EP1603554A1 (de) 2003-03-17 2005-12-14 Japan Tobacco Inc. Methode zur verbesserung der oralen bioverfuegbarkeit von s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanthioat
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
EP2902023A4 (de) 2012-09-28 2016-03-30 Santen Pharmaceutical Co Ltd Therapeutikum oder prophylaktikum für meibomdrüsendysfunktion oder meibomdrüsenblockierung
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
WO2020045807A1 (ko) 2018-08-31 2020-03-05 한국지질자원연구원 비흡수성 항생물질 및 점토광물의 복합체를 포함하는 조성물을 대상에게 경구투여하는 단계를 포함하는 헬리코박터 파일로리의 제균 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB772567A (en) * 1954-05-06 1957-04-17 Siegfried Fischl Preparation of stable, injectable bismuth-containing pharmaceutical compositions and the compositions formed thereby
WO1986005981A1 (en) * 1985-04-18 1986-10-23 Borody Thomas J Treatment of non-ulcer dyspepsia with bismuth salts
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
DE3686836T2 (de) * 1985-06-13 1993-03-04 Barry James Marshall Zusammensetzungen zur behandlung von magen-darmstoerungen.
US4959384A (en) * 1985-10-24 1990-09-25 Norwich Eaton Pharmaceuticals, Inc. Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
EP0282132B1 (de) * 1987-03-09 1992-09-30 The Procter & Gamble Company Zusammensetzungen und ihre Verwendung zur Behandlung von Magen-Darmstörungen
JP2733849B2 (ja) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
CH679582A5 (de) * 1988-07-18 1992-03-13 Glaxo Group Ltd
FI910088A (fi) * 1990-01-09 1991-07-10 Gist Brocades Nv Oral farmaceutisk komposition.
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
WO1992010302A1 (de) * 1990-12-04 1992-06-25 Mueller Werner Bewässerungsanlage für hallenböden von reithallen, treibhäusern u. dgl.
US5176698A (en) * 1991-01-09 1993-01-05 Scimed Life Systems, Inc. Vented dilatation cathether and method for venting
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions

Also Published As

Publication number Publication date
AU2458492A (en) 1993-03-25
IE922673A1 (en) 1993-03-24
ITRM920681A0 (it) 1992-09-18
RU2116071C1 (ru) 1998-07-27
MX9205313A (es) 1993-04-01
IL103213A (en) 2000-02-29
US5674858A (en) 1997-10-07
KR930005619A (ko) 1993-04-20
NO923643D0 (no) 1992-09-18
DE69232864D1 (de) 2003-01-16
ES2188582T3 (es) 2003-07-01
HK78197A (en) 1997-06-20
ITRM920681A1 (it) 1994-03-18
GB9120131D0 (en) 1991-11-06
PT533281E (pt) 2003-04-30
NO923643L (no) 1993-03-22
EP0533281B1 (de) 2002-12-04
IT1262993B (it) 1996-07-23
DE69232864T2 (de) 2003-11-20
IL103213A0 (en) 1993-02-21
KR100257367B1 (ko) 2000-05-15
CZ282840B6 (cs) 1997-10-15
SK280283B6 (sk) 1999-11-08
SK287892A3 (en) 1995-06-07
CY2012A (en) 1998-02-20
ZA927157B (en) 1993-06-15
JPH0692850A (ja) 1994-04-05
NZ244390A (en) 1997-06-24
BE1005808A5 (fr) 1994-02-01
HU211170A9 (en) 1995-11-28
US5668130A (en) 1997-09-16
CH685372A5 (fr) 1995-06-30
ATE228835T1 (de) 2002-12-15
CZ287892A3 (en) 1993-12-15
AU663520B2 (en) 1995-10-12
GB2259647B (en) 1995-11-29
EP0533281A1 (de) 1993-03-24
AT403656B (de) 1998-04-27
FR2682040A1 (fr) 1993-04-09
NO301456B1 (no) 1997-11-03
FR2682040B1 (fr) 1994-10-28
CA2078579A1 (en) 1993-03-21
US5629297A (en) 1997-05-13
GB9219749D0 (en) 1992-10-28
GB2259647A (en) 1993-03-24

Similar Documents

Publication Publication Date Title
ATA186692A (de) Pharmazeutische zusammensetzung
ATE101517T1 (de) Pharmazeutische zusammensetzung, enthaltend loratadin, ibuprofen und pseudoephedrin.
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
ATE134134T1 (de) Feste arzneizubereitungen zur oralen verabreichung mit verlängerter magenverweilzeit
IE862554L (en) Pharmaceutical compositions
IT1239542B (it) Composizione farmaceutica comprendente piroxicam e procedimento per lasua preparazione
DE3579730D1 (de) Eisen-3-hydroxypyron- oder 3-hydroxypyridon-komplexe und diese enthaltende pharmazeutische zusammensetzungen.
DK481388D0 (da) Calciumtilskud
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
DK598288D0 (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
IT1240683B (it) Composizione farmaceutica contenente egf
IT1229223B (it) Composizioni veterinarie sinergisticamente attive e procedimento per la loro preparazione.
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren
DE3871159D1 (de) Pharmazeutische und tieraerztliche zusammensetzungen.
ITMI913248A1 (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione e procedimento per la preparazione dei suddetti principi attivi
ATE76295T1 (de) Pharmazeutische und tieraerztliche zusammensetzungen.
ATE59776T1 (de) Pharmazeutische zusammensetzung und behandlung.
ATE66213T1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee